At Touchlight, we’re shaping the next era of genetic medicine and we believe that the future begins with the foundation of high-quality, scalable DNA. That’s why we’ve pioneered a suite of an enzymatic DNA technologies, Doggybone™ DNA (dbDNA™), mbDNA™, and z- dbDNA™. These next-generation alternatives to plasmid DNA overcome the bottlenecks of traditional systems. Our proprietary cell-free DNA platforms enable multi-gram DNA production in weeks, rather than the months taken to make plasmid DNA using traditional E.coli fermentation methods.
Whether you’re developing gene therapies, mRNA vaccines, or cell-based treatments, our technologies provide the speed, purity, and flexibility you need to advance your program from discovery to commercialisation.
